Skip to content
Triangle logo TriangleGet started
← Study library

NCT01839916 · REGISTRY CONDITION SEARCH

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2019-08-07

This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies. In a donor stem cell transplant, the donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Percentage of Patients Who Are Able to Receive at Least One DLI Treatment

→

outcome · POSTED

Progression Free Survival (PFS)

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Rate of Acute GVHD (aGVHD) With Any Grade

→

outcome · POSTED

Rate of Chronic GVHD (cGVHD)

→

outcome · POSTED

Treatment-related Mortality

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * INCLUSION CRITERIA PRIOR TO TRANSPLANT: * The clinical trial will be offered to all high risk (defined 3 below) patients with hematologic malignancies who require stem cell transplants as part of their standard of care using matched related or unrelated donors * Patients with high risk myeloid or lymphoid malignancies at stem cell transplant following American Society for Blood and Marrow Transplantation (ASBMT) criteria, including but not limited to conditions listed; these criteria apply BEFORE cyto-reductive therapy given within 28 days of planned conditioning: * Refractory acute myelogenous or lymphoid leukemia * Relapsed acute myelogenous or lymphoid leukemia * Myelodysplastic syndromes with 5% or more blasts * Chronic myelogenous leukemia in chronic phase 3 or more, blast phase presently, or second accelerated phase * Recurrent or refractory malignant lymphoma or Hodgkin's disease with less than a partial response at transplant * High risk chronic lymphocytic leukemia defined as no response or stable disease to the most recent treatment regimen * DONORS: Matched related or unrelated donor stem cell transplant (SCT) matched at human leukocyte antigen (HLA) A- B, C, and DRB1 by molecular methods; 7 of 8 matched donor acceptable for related donors * T-cell depletion with anti-thymocyte globulin (ATG) (rabbit or horse) or at least 30 mg of alemtuzumab total in the conditioning regimen * Immune suppression; planned post-transplant immune suppression should include tacrolimus or cyclosporin monotherapy (i.e., calcineurin inhibitor or CN) for alemtuzumab regimens and a second immune suppressant for ATG treated patients; other agents may be used if CN intolerance or toxicity occurs post-transplant * Zubrod performance status (PS) 0-2 or equivalent Karnofsky PS * Eligible for allogeneic transplant in the treating physicians' judgment and by institutional standards * ELIGIBILITY TO RECEIVE DLI POST-TRANSPLANT: * Donor lymphocytes available or able to be collected * No evidence of disease by standard morphology; minimal residual disease or molecular evidence of disease will not exclude * Absolute neutrophil count \>= 500/μl * Platelet count \>= 20,000/μl without transfusion for 7 days * Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =\< 5 x upper limit of normal (ULN) * Bilirubin =\< 3 x ULN * No evidence of grade II or higher acute GVHD or chronic GVHD at initiation of first DLI * No systemic corticosteroids or immunosuppressive drugs (topical acceptable); replacement steroids for adrenal insufficiency are not excluded Exclusion Criteria: * EXCLUSION CRITERIA PRIOR TO TRANSPLANT: * Pregnant or lactating females * Hepatitis B with positive viral load prior to transplant conditioning or hepatitis C virus * Human immune deficiency virus * Psychiatric illness that may make compliance to the clinical protocol unmanageable or may compromise the ability of the patient to give informed consent * Creatinine \>= 2.0 mg/dL * SGOT and SGPT \>= 5 x ULN; liver biopsy preferred for such patients * Bilirubin \>= 3 x ULN (unless Gilbert's syndrome) * Diffusing capacity of the lung for carbon monoxide (DLCO) \< 50% corrected for hemoglobin * Left ventricular ejection fraction or shortening fraction \< 40% * Unlikely to be able to procure additional donor lymphocytes
healthy Volunteers
false
maximum Age
75 Years
minimum Age
14 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: therapeutic allogeneic lymphocytes
    2. Other: laboratory biomarker analysis
    label
    Treatment (DLI)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (DLI)
    description
    Given IV
    name
    therapeutic allogeneic lymphocytes
    other Names
    1. ALLOLYMPH
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Treatment (DLI)
    description
    Correlative studies
    name
    laboratory biomarker analysis
    type
    OTHER
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
77
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Percentage of Patients Who Are Able to Receive at Least One DLI Treatment
    time Frame
    Up to 2 years
secondary Outcomes
  1. description
    Time to relapse or death as a result of any cause was evaluated at 2 years and the progression free survival rate was reported.
    measure
    Progression Free Survival (PFS)
    time Frame
    2 years
  2. description
    Computed using the Kaplan-Meier product-limit estimate and expressed as probabilities with a 95% CI.
    measure
    Overall Survival (OS)
    time Frame
    At 2 years
  3. description
    Estimated by cumulative incidence method.
    measure
    Rate of Acute GVHD (aGVHD) With Any Grade
    time Frame
    At 1 year and 2 year
  4. description
    Estimated by cumulative incidence method.
    measure
    Rate of Chronic GVHD (cGVHD)
    time Frame
    At 1 year and 2 year
  5. description
    Estimated by cumulative incidence method. Cumulative incidence of treatment-related mortality with relapse of the original disease as the competing risk will be calculated.
    measure
    Treatment-related Mortality
    time Frame
    At 2 year
Full study description
brief Summary
This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies. In a donor stem cell transplant, the donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect.
detailed Description
PRIMARY OBJECTIVES: I. To determine the feasibility of escalating dose regimen (EDR) donor lymphocyte infusion (DLI) as measured by the proportion of patients who receive at least one DLI. SECONDARY OBJECTIVES: I. To assess progression free survival (PFS) at 2 years after stem cell transplant (SCT) for high-risk hematologic malignancies receiving T-cell depleted grafts followed by escalating dose regimen (EDR) prophylactic DLI compared to historical controls not receiving DLI. II. To assess the safety of EDR DLI for high-risk hematologic malignancies as measured by cumulative incidence of severe grade III-IV acute graft-versus-host disease (GVHD). III. To measure outcomes of grade II-IV acute GVHD, non-relapse mortality, overall survival and chronic GVHD of EDR DLI. IV. To assess the full donor chimerism rate in the CD3 compartment and immune reconstitution after EDR DLI. OUTLINE: Patients receive DLI intravenously (IV). Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically for 2 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-400f6782564e6ed28361
      requested nct id
      NCT01839916
      primary nct id
      NCT01839916
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      payload sha256
      70f9bf163b777cf6c0fa6ee5dc3f9fb017eccc747e31d328476d87d858453e6b
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-400f6782564e6ed28361
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01839916
      occurrences
      1. context exact
        NCT01839916
        end
        11
        exact text
        NCT01839916
        start
        0
      offset unit
      unicode_code_points
      query cond
      Peripheral T-Cell Non-Hodgkin Lymphoma
      query disease state id
      ds-peripheral-t-cell-non-hodgkin-lymphoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      source json pointer
      /studies/0/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      188952e079da1c11fadd267a1745cf4eb6c2a6c542b3075b5279ef3f5b16d703
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-5d4c98e9fabab00f8ea5
      requested nct id
      NCT01839916
      primary nct id
      NCT01839916
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
      payload sha256
      f3691a21412c2df865f0e60d9c56418a076204ebd8f9b3ac55d9d32acf91ff2c
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-5d4c98e9fabab00f8ea5
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01839916
      occurrences
      1. context exact
        NCT01839916
        end
        11
        exact text
        NCT01839916
        start
        0
      offset unit
      unicode_code_points
      query cond
      Testicular Cancer
      query disease state id
      ds-testicular-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-testicular-cancer-000.json
      source file sha256
      9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
      source json pointer
      /studies/0/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      188952e079da1c11fadd267a1745cf4eb6c2a6c542b3075b5279ef3f5b16d703
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-8eaf4a2dcc0738d1e785
      requested nct id
      NCT01839916
      primary nct id
      NCT01839916
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      a4be8fb2a7db9247bdfed231ef84ae19b3babbe8d619ebf7403cceb730eae2d4
      payload sha256
      e477578192e84b4faab61ab73c6e257b6aae2ee71ea2989581af190f721ec859
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-8eaf4a2dcc0738d1e785
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01839916
      occurrences
      1. context exact
        NCT01839916
        end
        11
        exact text
        NCT01839916
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Myelodysplastic Neoplasms
      query disease state id
      ds-myelodysplastic-neoplasms-pediatric
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-myelodysplastic-neoplasms-000.json
      source file sha256
      a4be8fb2a7db9247bdfed231ef84ae19b3babbe8d619ebf7403cceb730eae2d4
      source json pointer
      /studies/0/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      188952e079da1c11fadd267a1745cf4eb6c2a6c542b3075b5279ef3f5b16d703
    4. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-948de8ab16a6e032d6f2
      requested nct id
      NCT01839916
      primary nct id
      NCT01839916
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      63db6a836faa90e018d0c1a39944e6262f4f37fc18f6173aedc5fea7f116bb0a
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-948de8ab16a6e032d6f2
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01839916
      occurrences
      1. context exact
        NCT01839916
        end
        11
        exact text
        NCT01839916
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/1/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      188952e079da1c11fadd267a1745cf4eb6c2a6c542b3075b5279ef3f5b16d703
    5. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-a9245284f42f3d32e6fb
      requested nct id
      NCT01839916
      primary nct id
      NCT01839916
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
      payload sha256
      32f1f1069fa0e3272d69ddf6a4a1e2e65028cb3f0335d785e736529fc5ce3986
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-a9245284f42f3d32e6fb
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01839916
      occurrences
      1. context exact
        NCT01839916
        end
        11
        exact text
        NCT01839916
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Chronic Myeloid Leukemia
      query disease state id
      ds-chronic-myeloid-leukemia-pediatric
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-chronic-myeloid-leukemia-000.json
      source file sha256
      193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
      source json pointer
      /studies/0/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      188952e079da1c11fadd267a1745cf4eb6c2a6c542b3075b5279ef3f5b16d703
    6. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-ab4659c20df9b8a37bad
      requested nct id
      NCT01839916
      primary nct id
      NCT01839916
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
      payload sha256
      af6c665bfcf583bfe695592adee7cfed2e8cd317577e84c0247f0250faf021bb
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-ab4659c20df9b8a37bad
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01839916
      occurrences
      1. context exact
        NCT01839916
        end
        11
        exact text
        NCT01839916
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hairy Cell Leukemia
      query disease state id
      ds-hairy-cell-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hairy-cell-leukemia-000.json
      source file sha256
      8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
      source json pointer
      /studies/0/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      188952e079da1c11fadd267a1745cf4eb6c2a6c542b3075b5279ef3f5b16d703
    7. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-bf3193bf9a95ef178098
      requested nct id
      NCT01839916
      primary nct id
      NCT01839916
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
      payload sha256
      7f9f4d8ab3c737ef1fffd25f270bb7ce7cfb1108c02728090d1a7c487de38be3
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-bf3193bf9a95ef178098
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01839916
      occurrences
      1. context exact
        NCT01839916
        end
        11
        exact text
        NCT01839916
        start
        0
      offset unit
      unicode_code_points
      query cond
      Small Intestine Cancer
      query disease state id
      ds-small-intestine-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-small-intestine-cancer-000.json
      source file sha256
      69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
      source json pointer
      /studies/0/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      188952e079da1c11fadd267a1745cf4eb6c2a6c542b3075b5279ef3f5b16d703
    8. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-c44cbba87196886be7f3
      requested nct id
      NCT01839916
      primary nct id
      NCT01839916
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
      payload sha256
      a505b822e88d0798ec59667ebe9082b2291f850a51fe5c60655cadd9467285d9
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-c44cbba87196886be7f3
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01839916
      occurrences
      1. context exact
        NCT01839916
        end
        11
        exact text
        NCT01839916
        start
        0
      offset unit
      unicode_code_points
      query cond
      Acute Undifferentiated Leukemia
      query disease state id
      ds-acute-undifferentiated-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-acute-undifferentiated-leukemia-000.json
      source file sha256
      a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
      source json pointer
      /studies/0/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      188952e079da1c11fadd267a1745cf4eb6c2a6c542b3075b5279ef3f5b16d703

    Preserved source evidence · Not medical advice